References
- Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 2011;68:13–16
- Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439–51
- Scarpellini E, Tack J. Obesity and metabolic syndrome: an inflammatory condition. Dig Dis 2012;30:148–53
- Stefan N, Stumvoll M. Adiponectin – its role in metabolism and beyond. Horm Metab Res 2002;34:469–74
- Trujillo ME, Scherer PE. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167–75
- Chakrabarti J. Serum leptin level in women with polycystic ovary syndrome: correlation with adiposity, insulin, and circulating testosterone. Ann Med Health Sci Res 2013;3:191–6
- Jacobs HS, Conway GS. Leptin, polycystic ovaries and polycystic ovary syndrome. Hum Reprod Update 1999;5:166–71
- Olszanecka-Glinianowicz M, Kuglin D, Dąbkowska-Huć A, Skałba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;154:51–6
- Wang Y, Xie X, Zhu W. Serum adiponectin and resistin levels in patients with polycystic ovarian syndrome and their clinical implications. J Huazhong Univ Sci Technolog Med Sci 2010;30:638–42
- Pehlivanov B, Mitkov M. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2009;14:153–9
- Garruti G, Depalo R, Vita MG, et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online 2009;19:552–63
- Svendsen PF, Christiansen M, Hedley PL, et al. Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertil Steril 2012;98:235–41
- Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129–39
- Liang SJ, Hsu CS, Tzeng CR, et al. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Hum Reprod 2011;26:3443–9
- Azziz R, Carmina E, Dewailly D, et al; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88
- Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009;26:163–70
- Azziz R, Carmina E, Dewailly D, et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237–45
- Golbahar J, Das NM, Al-Ayadhi MA, Gumaa K. Leptin-to-adiponectin, adiponectin-to-leptin ratios, and insulin are specific and sensitive markers associated with polycystic ovary syndrome: a case-control study from Bahrain. Metab Syndr Relat Disord 2012;10:98–102
- Wang Q, Guo T, Tao Y, et al. Association between serum adipocyte factor level and insulin resistance in polycystic ovarian syndrome. Gynecol Endocrinol 2011;27:931–4